ESPECIALIDADES jueves, 28 de marzo de 2024  
Medicina regenerativa
Medicina regenerativa
Portal de Infomed
 
 
Total de artículos: 75 mostrando: 51 - 60

página 6 de 8   1  2  3  4  5  6  7  8  
Titulares

Cardiac stem cells in patients with ischaemic cardiomyopathy (SCIPIO): initial results of a randomised phase 1 trial.R Bolli.Lancet 2011

Roberto Bolli, Atul R Chugh, Domenico D?Amario, John H Loughran, Marcus F Stoddard, Sohail Ikram, Garth M Beache, Stephen G Wagner,
Annarosa Leri, Toru Hosoda, Fumihiro Sanada, Julius B Elmore, Polina Goichberg, Donato Cappetta, Naresh K Solankhi, Ibrahim Fahsah,
D Gregg Rokosh, Mark S Slaughter, Jan Kajstura, Piero Anversa
Summary
Background c-kit-positive, lineage-negative cardiac stem cells (CSCs) improve post-infarction left ventricular (LV) dysfunction when administered to animals. We under took a phase 1 trial (Stem Cell Infusion in Patients with Ischemic cardiomyopathy [SCIPIO]) of autologous CSCs for the treatment of heart failure resulting from ischaemic heart disease.
Methods In stage A of the SCIPIO trial, patients with post-infarction LV dysfunction (ejection fraction [EF] ?40%)before coronary artery bypass grafting were consecutively enrolled in the treatment and control groups. In stage B,patients were randomly assigned to the treatment or control group in a 2:3 ratio by use of a computer-generated block randomisation scheme. 1 million autologous CSCs were administered by intracoronary infusion at a mean of 113 days (SE 4) after surgery; controls were not given any treatment. Although the study was open label, the
echocardiographic analyses were masked to group assignment. The primary endpoint was short-term safety of CSCs and the secondary endpoint was effi cacy. A per-protocol analysis was used. This study is registered with ClinicalTrials.
gov, number NCT00474461.
Findings This study is still in progress. 16 patients were assigned to the treatment group and seven to the control group; no CSC-related adverse eff ects were reported. In 14 CSC-treated patients who were analysed, LVEF increased from 30·3% (SE 1·9) before CSC infusion to 38·5% (2·8) at 4 months after infusion (p=0·001). By contrast, in seven control patients, during the corresponding time interval, LVEF did not change (30·1% [2·4] at 4 months after CABG
vs 30·2% [2·5] at 8 months after CABG). Importantly, the salubrious eff ects of CSCs were even more pronounced at 1 year in eight patients (eg, LVEF increased by 12·3 ejection fraction units [2·1] vs baseline, p=0·0007). In the seven treated patients in whom cardiac MRI could be done, infarct size decreased from 32·6 g (6·3) by 7·8 g (1·7; 24%) at
4 months (p=0·004) and 9·8 g (3·5; 30%) at 1 year (p=0·04).
Interpretation These initial results in patients are very encouraging. They suggest that intracoronary infusion of autologous CSCs is eff ective in improving LV systolic function and reducing infarct size in patients with heart failure after myocardial infarction, and warrant further, larger, phase 2 studies.
Funding University of Louisville Research Foundation and National Institutes of Health.
Lancet 2011; 378: 1847?57


 
Total de artículos: 75 mostrando: 51 - 60

página 6 de 8   1  2  3  4  5  6  7  8  
 
: Editora Principal, Especialista de II Grado en Hematología, J' Dpto. Trasplante de Células Progenitoras Hematopoyéticas | - Instituto de Hematología e Inmunología, MINSAP | Calzada de Aldabo y Calle E. Altahabana, Ciudad de La Habana, 10300 Cuba Telefs: (537) 6431648 y (537) 6438042 Horario de atención: 8:30 AM a 5:00 PM, de Lunes a Viernes


Nosotros suscribimos Los Principios del código HONcode de la Fundación Salud en la Red
 Nosotros suscribimos
 los Principios
 HONcode.
 Compruébelo aquí
Webs Médicas de Calidad Contenido Digital Cubano 2005 Premio Stockholm Challenge 2002